Overwhelmed and confused, pharma marketers? Time to embrace 'New Science,' consultancy says

molecule
The building blocks to better pharma marketing should include technology and New Science, Accenture says. (UCSF)

Pharma marketers unsure of what customers want should embrace “New Science,” according to a new survey and report from Accenture Life Sciences.

Half of the pharma marketing executives the consultancy surveyed said they didn't have a good understanding of the wants and needs of their customers, which include patients, healthcare providers and payers. That’s where New Science, or what Accenture calls the meeting point between technology and science, can help.

New Science requires that companies go beyond just developing and marketing drugs or devices by using technology, by itself or in conjunction with treatments, to figure out and solve unmet needs, Elizabeth Otterman, managing director in Accenture’s Life Sciences business, said in an email interview.

Watch the Free Webinar

Chemistry Through Biology: Translating Molecular Biology Technologies into Practical Processes for API Production

Learn about the key advances and critical hurdles in transforming emerging molecular biology technologies into practical applications with commercially viable processes.

RELATED: Tipping point? Digital communications from pharma finally get their due with doctors

“Marketing a treatment is no longer enough; companies must bring patient outcomes to market by using insight to pair treatment, technology and experience,” she said. “That means companies need to create operating models that are organized around new business goals, driven by meaningful insights from customers, enabled by technology such as AI, advanced analytics and machine learning, and powered by a future workforce with new skills and competencies.”

Accenture advocates three overall changes for pharma marketers to continue to drive growth. Become customer obsessed; overhaul the company’s marketing mindset, skillset and toolset; and use data better across the organization and outside of it, Otterman said.

One specific way to drive the move forward is to get the CEO and board involved and engaged, along with individual teams inside the company, she said. Some ways include showing best-in-class examples of how to delight customers and offering ongoing education on how to use AI, machine learning and advanced analytics to discover and apply new insights.

RELATED: Pharma's got its chief digital officers. Now let's see results: Sanofi exec

“Digital technologies and advanced analytics have the potential to allow an unprecedented level of customer intimacy. Start capturing this potential by identifying new ways of working that bring together different skills and experience from across the organization,” Otterman said.

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.